Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 17.24 SEK -4.8%
Market Cap: 805m SEK
Have any thoughts about
Moberg Pharma AB (publ)?
Write Note

Moberg Pharma AB (publ)
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Moberg Pharma AB (publ)
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Moberg Pharma AB (publ)
STO:MOB
Research & Development
-kr2.4m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Research & Development
-kr557.9m
CAGR 3-Years
-34%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Research & Development
-kr746.4m
CAGR 3-Years
-55%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Moberg Pharma AB (publ)
Glance View

Market Cap
790.1m SEK
Industry
Pharmaceuticals

Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.

MOB Intrinsic Value
0.6 SEK
Overvaluation 97%
Intrinsic Value
Price

See Also

What is Moberg Pharma AB (publ)'s Research & Development?
Research & Development
-2.4m SEK

Based on the financial report for Dec 31, 2023, Moberg Pharma AB (publ)'s Research & Development amounts to -2.4m SEK.

What is Moberg Pharma AB (publ)'s Research & Development growth rate?
Research & Development CAGR 3Y
26%

The average annual Research & Development growth rates for Moberg Pharma AB (publ) have been 26% over the past three years .

Back to Top